Sarepta Therapeutics (NASDAQ:SRPT) Upgraded at Deutsche Bank

Deutsche Bank upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from a sell rating to a hold rating in a research report released on Tuesday morning, MarketBeat Ratings reports. Deutsche Bank currently has $18.00 price objective on the biotechnology company’s stock, up from their prior price objective of $14.00.

A number of other equities analysts have also recently commented on SRPT. Robert W. Baird set a $18.00 target price on Sarepta Therapeutics in a report on Friday, November 6th. William Blair raised Sarepta Therapeutics to a “hold” rating in a research note on Wednesday, September 23rd. Wall Street Zen cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Zacks Research downgraded Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, October 5th. Finally, HC Wainwright restated a “sell” rating and issued a $5.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 5th. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and six have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of “Hold” and an average target price of $23.67.

Sarepta Therapeutics Stock Down 4.0%

SRPT stock opened at $16.01 on Tuesday. The stock has a market capitalization of $1.72 billion, a P/E ratio of -11.69, a P/E/G ratio of 0.39 and a beta of 0.45. The firm has a 50-day simple moving average of $18.73 and a 200-day simple moving average of $18.54. The company has a quick ratio of 2.13, a current ratio of 3.46 and a debt-to-equity ratio of 0.46. Sarepta Therapeutics has a 52 week low of $14.68 and a 52 week high of $24.68.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. Sarepta Therapeutics had a negative net margin of 5.86% and a negative return on equity of 0.20%. The firm had revenue of $381.35 million for the quarter, compared to analyst estimates of $352.20 million. During the same period last year, the company posted ($0.13) EPS. Sarepta Therapeutics’s quarterly revenue was down 4.5% compared to the same quarter last year. Equities analysts forecast that Sarepta Therapeutics will post 3.27 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $341,339,000. First Trust Advisors LP increased its holdings in shares of Sarepta Therapeutics by 107.6% in the first quarter. First Trust Advisors LP now owns 4,135,788 shares of the biotechnology company’s stock valued at $89,995,000 after purchasing an additional 2,143,211 shares during the last quarter. Bank of America Corp DE acquired a new stake in shares of Sarepta Therapeutics in the second quarter valued at approximately $36,946,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Sarepta Therapeutics in the second quarter valued at approximately $17,494,000. Finally, Legal & General Group Plc acquired a new stake in shares of Sarepta Therapeutics in the second quarter valued at approximately $15,771,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics is a biotechnology company focused on developing genetic medicines for rare diseases, with an emphasis on Duchenne muscular dystrophy (DMD). Its research includes RNA-based treatments designed to affect how genetic instructions are processed, as well as gene therapy approaches. The company’s DMD medicines include exon-skipping therapies such as eteplirsen (Exondys 51), golodirsen (Vyondys 53) and casimersen (Amondys 45). Each is intended for patients with a specific genetic mutation and works by helping cells produce a shortened form of dystrophin, a protein affected by DMD.